{"id":"NCT04735432","sponsor":"argenx","briefTitle":"Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis","officialTitle":"A Phase 3, Randomized, Open-Label, Parallel-Group Study to Compare the Pharmacodynamics, Pharmacokinetics, Efficacy, Safety, Tolerability, and Immunogenicity of Multiple Subcutaneous Injections of Efgartigimod PH20 SC With Multiple Intravenous Infusions of Efgartigimod in Patients With Generalized Myasthenia Gravis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-02-05","primaryCompletion":"2021-11-02","completion":"2021-12-13","firstPosted":"2021-02-03","resultsPosted":"2023-02-28","lastUpdate":"2023-02-28"},"enrollment":110,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Generalized Myasthenia Gravis"],"interventions":[{"type":"BIOLOGICAL","name":"efgartigimod PH20 SC","otherNames":[]},{"type":"BIOLOGICAL","name":"efgartigimod IV","otherNames":[]}],"arms":[{"label":"efgartigimod PH20 SC","type":"EXPERIMENTAL"},{"label":"efgartigimod","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to investigate the Pharmacodynamics (PD), Pharmacokinetics (PK), safety, tolerability, immunogenicity, and clinical efficacy of efgartigimod coformulated with recombinant human hyaluronidase PH20 (rHuPH20) as compared to efgartigimod IV infused in patients with generalized myasthenia gravis (gMG). The study duration is approximately 12 weeks. After screening, patients will be randomized to receive either efgartigimod infusions or efgartigimod PH20 subcutaneously (SC)","primaryOutcome":{"measure":"Percent Change From Baseline in Total IgG Levels at Day 29 (mITT Analysis Set)","timeFrame":"From week 0 to week 4","effectByArm":[{"arm":"Efgartigimod PH20 SC","deltaMin":-66.4,"sd":null},{"arm":"Efgartigimod IV","deltaMin":-62.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":47,"countries":["United States","Belgium","Georgia","Germany","Hungary","Italy","Japan","Netherlands","Poland","Russia","Spain"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":55},"commonTop":["Headache","Injection site rash","Myasthenia gravis","Injection site erythema","Fatigue"]}}